Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitor
Biotech
Cogent eyes FDA approval after clearing another ph. 3 hurdle
A combo including the company's tyrosine kinase inhibitor scored a 46% objective response rate, compared to 26% for monotherapy.
Darren Incorvaia
Nov 10, 2025 10:57am
JPM25: M&A strategist GSK acquires IDRx for $1B upfront
Jan 13, 2025 2:00am
Alumis raises $259M in 2024's largest biotech round so far
Mar 6, 2024 8:00am
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
May 31, 2023 9:45am
Gilead culls 3 programs, including 2 of 3 KRAS4 indications
Feb 3, 2023 5:45am
FDA rejection prompts Spectrum to cut 75% of R&D workforce
Nov 28, 2022 7:50am
